Dr. Reddy's Labs Saved From Poor India Showing By North America Market Growth, Biosimilars
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Dr. Reddy's Laboratories Ltd. faced an unexpected slowdown in its home market as sales growth in India slipped to just 6% during the first quarter - remarkably lower than the industry average of 14% to 15% - but a 69% rise in sales of its biosimilars products like monoclonal antibody Reditux (rituximab) powered revenues to a respectable $66 million, against $62 million achieved during the same period last year
You may also be interested in...
Super Generics – The Next Step For Generic Players As Commoditized Drugs Yield Less Margins – DIA India Conference
It takes tremendous efforts but generic companies eye complex drugs for lasting gains, said DIA India speakers.
After Years Of Partner Search, India's Dr. Reddy's Forms JV With Fujifilm To Tap Japanese Generics Market
MUMBAI - After years of desire to be in the Japanese generics drugs business, Dr. Reddy's Laboratories Ltd. CEO G.V. Prasad reached that milestone in the signing of a memorandum of understanding with Fujifilm Corp. CEO Shigetaka Komori
After Years Of Partner Search, India's Dr. Reddy's Forms JV With Fujifilm To Tap Japanese Generics Market
MUMBAI - After years of desire to be in the Japanese generics drugs business, Dr. Reddy's Laboratories Ltd. CEO G.V. Prasad reached that milestone in the signing of a memorandum of understanding with Fujifilm Corp. CEO Shigetaka Komori